Demarteau N - Search Results

1

Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models?

Standaert B, Demarteau N, Talbird S, Mauskopf J. Standaert B, et al. Among authors: demarteau n. Vaccine. 2010 Nov 19;28 Suppl 6:G30-8. doi: 10.1016/j.vaccine.2010.06.015. Vaccine. 2010. PMID: 21075268

2

Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer.

Demarteau N, Standaert B. Demarteau N, et al. J Med Econ. 2010;13(2):324-38. doi: 10.3111/13696998.2010.490481. J Med Econ. 2010. PMID: 20504110 Free article.

3

Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination.

Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, Mantovani L, Capri S, Chou CY, Standaert B, Annemans L. Debicki D, et al. Among authors: demarteau n. Vaccine. 2008 Sep 15;26 Suppl 5:F16-28. doi: 10.1016/j.vaccine.2008.02.040. Vaccine. 2008. PMID: 18992379 Review.

4

A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer.

Demarteau N, Detournay B, Tehard B, El Hasnaoui A, Standaert B. Demarteau N, et al. Int J Public Health. 2011 Apr;56(2):153-62. doi: 10.1007/s00038-010-0216-6. Epub 2010 Nov 26. Int J Public Health. 2011. PMID: 21110060 Free PMC article.

5

Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program.

Demarteau N, Breuer T, Standaert B. Demarteau N, et al. Pharmacoeconomics. 2012 Apr;30(4):337-53. doi: 10.2165/11591560-000000000-00000. Pharmacoeconomics. 2012. PMID: 22409292

6

Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.

Colantonio L, Gómez JA, Demarteau N, Standaert B, Pichón-Rivière A, Augustovski F. Colantonio L, et al. Among authors: demarteau n. Vaccine. 2009 Sep 4;27(40):5519-29. doi: 10.1016/j.vaccine.2009.06.097. Epub 2009 Jul 17. Vaccine. 2009. PMID: 19616499

7

Public health impact of human papillomavirus vaccination on prevention of cervical cancer in France.

El Hasnaoui A, Demarteau N, Granados D, Standaert B, Detournay B. El Hasnaoui A, et al. Among authors: demarteau n. Int J Public Health. 2012 Feb;57(1):149-58. doi: 10.1007/s00038-011-0273-5. Epub 2011 Jun 28. Int J Public Health. 2012. PMID: 21710187

8

How Do Decision Makers in Europe Value Other Economic Evaluation Tools Than Cost-Effectiveness Analysis for Vaccines?

Höhne JM, Demarteau N, Saka Ö, Standaert B, Kleintjens J. Höhne JM, et al. Among authors: demarteau n. Value Health. 2014 Nov;17(7):A675-6. doi: 10.1016/j.jval.2014.08.2509. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202482 Free article. No abstract available.

9

Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.

Suárez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, Torvinen S, Demarteau N, Standaert B. Suárez E, et al. Among authors: demarteau n. Vaccine. 2008 Sep 15;26 Suppl 5:F29-45. doi: 10.1016/j.vaccine.2008.05.069. Vaccine. 2008. PMID: 18992380

10

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.

Demarteau N, Van Kriekinge G, Simon P. Demarteau N, et al. Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15. Vaccine. 2013. PMID: 23777952 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters